Skip to main
SLNO

Soleno Therapeutics (SLNO) Stock Forecast & Price Target

Soleno Therapeutics (SLNO) Analyst Ratings

Based on 8 analyst ratings
Buy
Strong Buy 13%
Buy 38%
Hold 50%
Sell 0%
Strong Sell 0%

Bulls say

Soleno Therapeutics is set to be acquired at a premium of 34% to its current share price, driven by its FDA-approved product VYKAT XR which has shown strong early adoption and is expected to generate peak annual sales of $2.3B in the U.S. by 2034. The transaction is fully funded and expected to close swiftly without financing contingencies, underscoring the company's healthy financial position and potential for value maximization through M&A or licensing activities. The recent estimates have been updated to reflect higher revenue and earnings projections, further solidifying the positive outlook for Soleno Therapeutics.

Bears say

Soleno Therapeutics is facing significant risks, including regulatory issues that could hinder the completion of its acquisition and fail to secure approval for its product DCCR in Europe. Valuation based on a discounted cash flow approach and an effective tax rate of 29.84% yields a total firm value of $6.23B and a 12-month price objective of $120 per share. Additional risks to consider are the potential for slow uptake of VYKAT XR in the US market, generic erosion of its franchise, and dilution risk in the long term.

Soleno Therapeutics (SLNO) has been analyzed by 8 analysts, with a consensus rating of Buy. 13% of analysts recommend a Strong Buy, 38% recommend Buy, 50% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Soleno Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Soleno Therapeutics (SLNO) Forecast

Analysts have given Soleno Therapeutics (SLNO) a Buy based on their latest research and market trends.

According to 8 analysts, Soleno Therapeutics (SLNO) has a Buy consensus rating as of May 15, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $74.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $74.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Soleno Therapeutics (SLNO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.